JP Morgan Chase
CBIO

JP Morgan Chase’s Crescent Biopharma CBIO Stock Holding History

JP Morgan Chase’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-360
Closed -$449K – 5845
2019
Q1 		$449K Buy
+360
New +$412K ﹤0.01% 4262
2018
Q4 		– Sell
-360
Closed -$518K – 5767
2018
Q3 		$518K Buy
+360
New +$544K ﹤0.01% 4263
2018
Q2 		– Sell
-540
Closed -$876K – 5584
2018
Q1 		$876K Sell
540
-270
-33% -$562K ﹤0.01% 3747
2017
Q4 		$1.36M Buy
+810
New +$1.07M ﹤0.01% 3558

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase's CBIO Position: Q2 2026 in Review

JP Morgan Chase reduced its Crescent Biopharma (CBIO) stake by 78% in Q2 2026, selling an estimated $624K and leaving 9,020 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #5732.

JP Morgan Chase first reported a position in CBIO in Q4 2014 and has held it in 33 quarters since. The position peaked at $763K in Q4 2020. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • JP Morgan Chase held 9,020 shares of Crescent Biopharma worth $162K as of Q2 2026.
  • JP Morgan Chase sold 31,984 Crescent Biopharma shares in Q2 2026, an estimated $624K.
  • Crescent Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5732 holding.
  • JP Morgan Chase first reported a position in Crescent Biopharma in Q4 2014 and has held it in 33 quarters since.
  • JP Morgan Chase's Crescent Biopharma position peaked at $763K in Q4 2020.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.